Table 4.
miRNAs affecting the response of lung cancer cells to chemotherapy.
| miRNA | Chemotherapeutic Agent | Effect on Chemotherapy | Remarks | Refs. |
|---|---|---|---|---|
| miRNA -181 | Cisplatin | Sensitivity | PTEN upregulation Inhibition of PI3K/Akt/mTOR signaling Apoptosis induction Disrupting cancer metastasis |
[249] |
| miRNA -29b-3p | Cisplatin | Sensitivity | Disrupting cell viability Reducing proliferation Inducing apoptosis via Bax upregulation Triggering PTEN signaling |
[228] |
| miRNA -23a | Erlotinib | Resistance | Silencing miRNA-23a restores PTEN expression to suppress PI3K/Akt signaling, leading to erlotinib sensitivity | [229] |
| miRNA -134/487b/655 | Gefitinib | Resistance | Inducing TGF-b1 signaling in reducing PTEN expression Enhancing cancer metastasis via EMT induction Providing chemoresistance |
[246] |
| miRNA -21 | Gefitinib | Resistance | Reverse relationship between miRNA-21 and PTEN Activation of Akt and ERK signaling pathways Association with poor prognosis |
[232] |
| miRNA -21 | Cisplatin | Resistance | Hypoxia induces exsoaomal transfer of miRNA-21 Exerting PTEN inhibition |
[233] |
| miRNA -92b | Cisplatin | Resistance | Establishing cancer proliferation Reducing sensitivity to chemotherapy PTEN inhibition |
[248] |
| miRNA -1269b | Cisplatin | Resistance | Enhancing cancer cell growth Apoptosis inhibition Inducing PI3K/Akt signaling via PTEN downregulation |
[237] |
| miRNA -21 | EGFR-TKI | Resistance | Negative association with PTEN expression Triggering PI3K/Akt signaling Reducing chemosensitivity |
[234] |